Pipeline of Next-Generation Single- and Dual Payload ADCs
We are at the forefront of next-generation ADCs and, through our cell-free platform, we have fully optimized the antibody, linker, and payload to expand the therapeutic window, minimizing toxicity and maximizing efficacy.
We are advancing multiple candidates in parallel to address large market opportunities. Our single-payload ADCs, STRO-004 and STRO-006, are designed with best-in-class potential for complex targets across multiple tumor types where competition remains limited. Our dual-payload ADC programs represent a new class of supercharged ADCs designed to overcome resistance and delay disease progression. By combining distinct payloads, these programs have the potential to deliver improved clinical benefit, tolerability, and durability of response.
Oncology Programs
PROGRAM
MODALITY/
TARGET
INDICATION
DISCOVERY
PRECLINICAL
PHASE 1/1B
PHASE 2
PHASE 3/
REGISTRATIONAL
INFO/
PARTNER
ASP2998
2nd iADC
*Dual Payload Immunostimulatory ADC (iADC)
Non-Oncology Programs
PROGRAM
MODALITY/
TARGET
INDICATION
DISCOVERY
PRECLINICAL
PHASE 1/1B
PHASE 2
PHASE 3/
REGISTRATIONAL
PARTNER
VAX-31
Conjugate Vaccine
Pneumococcal Disease
VAX-24
Conjugate Vaccine
Pneumococcal Disease
Clinical Trials
Patients are Sutro’s passion and purpose. Our ongoing clinical trials represent our commitment to delivering new, life-changing therapies to people who need them most. Interested in learning more? Explore our clinical trials below.
STRO-004 | Tissue Factor
STRIVE-01: Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors.
STRO-006 | Integrin β6
A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary anti-Tumor Activity of STRO‑006 in Adults with Refractory Solid Tumors That Are Recurrent or Metastatic
For questions, please contact us at patients@sutrobio.com